Nicola Normanno

Summary

Publications

  1. ncbi request reprint Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer
    Nicola Normanno
    Cell Biology and Biotherapy Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale IRCCS, Napoli, Italy Electronic address
    Lung Cancer 85:314-9. 2014
  2. pmc Expression and functional role of CRIPTO-1 in cutaneous melanoma
    A De Luca
    Cell Biology and Biotherapy Unit, Research Department, INT Fondazione Pascale, Naples 80131, Italy
    Br J Cancer 105:1030-8. 2011
  3. pmc Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
    Pietro Carotenuto
    Pharmacogenomic Laboratory, CROM Centro Ricerche Oncologiche di Mercogliano, Avellino, Italy
    Pharmgenomics Pers Med 4:1-9. 2011
  4. doi request reprint Prognostic applications of gene expression signatures in breast cancer
    Nicola Normanno
    Cell Biology and Biotherapy Unit, INT Fondazione Pascale, Naples, Italy
    Oncology 77:2-8. 2009
  5. ncbi request reprint Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
    Nicola Normanno
    Cell Biology and Preclinical Models, INT Fondazione Pascale, Naples, Italy
    Endocr Relat Cancer 12:721-47. 2005
  6. ncbi request reprint Epidermal growth factor receptor (EGFR) signaling in cancer
    Nicola Normanno
    Cell Biology and Preclinical Models Unit, INT Fondazione Pascale, 80131 Naples, Italy
    Gene 366:2-16. 2006
  7. ncbi request reprint Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application?
    Nicola Normanno
    Cell Biology and Preclinical Models Unit, National Cancer Institute, INT Fondazione Pascale, Via Mariano Semmola, 80131 Naples, Italy
    Endocr Relat Cancer 13:3-6. 2006
  8. doi request reprint Target-based therapies in breast cancer: current status and future perspectives
    Nicola Normanno
    Cell Biology and Biotherapy Unit, INT Fondazione Pascale, 80131 Naples, Italy
    Endocr Relat Cancer 16:675-702. 2009
  9. ncbi request reprint Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling
    Nicola Normanno
    Cell Biology and Preclinical Models Unit, INT Fondazione Pascale, 80131, Naples, Italy
    Breast Cancer Res Treat 112:25-33. 2008
  10. ncbi request reprint CRIPTO-1: a novel target for therapeutic intervention in human carcinoma
    Nicola Normanno
    Department of Experimental Oncology, INT Fondazione Pascale, Via Mariano Semmola, I 80131 Naples, Italy
    Int J Oncol 25:1013-20. 2004

Collaborators

Detail Information

Publications57

  1. ncbi request reprint Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer
    Nicola Normanno
    Cell Biology and Biotherapy Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale IRCCS, Napoli, Italy Electronic address
    Lung Cancer 85:314-9. 2014
    ..We assessed the prognostic value of CTCs in patients with extensive SCLC...
  2. pmc Expression and functional role of CRIPTO-1 in cutaneous melanoma
    A De Luca
    Cell Biology and Biotherapy Unit, Research Department, INT Fondazione Pascale, Naples 80131, Italy
    Br J Cancer 105:1030-8. 2011
    ..CRIPTO-1 (CR-1) is involved in the pathogenesis and progression of human carcinoma of different histological origin. In this study we addressed the expression and the functional role of CR-1 in cutaneous melanoma...
  3. pmc Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
    Pietro Carotenuto
    Pharmacogenomic Laboratory, CROM Centro Ricerche Oncologiche di Mercogliano, Avellino, Italy
    Pharmgenomics Pers Med 4:1-9. 2011
    ..Therefore, gefitinib is a major breakthrough for the management of EGFR mutant NSCLC patients and represents the first step toward personalized treatment of NSCLC...
  4. doi request reprint Prognostic applications of gene expression signatures in breast cancer
    Nicola Normanno
    Cell Biology and Biotherapy Unit, INT Fondazione Pascale, Naples, Italy
    Oncology 77:2-8. 2009
    ..By using these approaches, gene expression techniques might significantly improve our ability to predict the risk of recurrence and to tailor the treatment for each individual breast cancer patient...
  5. ncbi request reprint Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
    Nicola Normanno
    Cell Biology and Preclinical Models, INT Fondazione Pascale, Naples, Italy
    Endocr Relat Cancer 12:721-47. 2005
    ..More importantly, the knowledge of the mechanisms involved in the resistance of breast cancer cells to endocrine therapy offers potential for novel therapeutic strategies...
  6. ncbi request reprint Epidermal growth factor receptor (EGFR) signaling in cancer
    Nicola Normanno
    Cell Biology and Preclinical Models Unit, INT Fondazione Pascale, 80131 Naples, Italy
    Gene 366:2-16. 2006
    ..This phenomenon is also important for therapeutic approaches, since the response to anti-EGFR agents might depend on the total level of expression of ErbB receptors and ligands in tumor cells...
  7. ncbi request reprint Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application?
    Nicola Normanno
    Cell Biology and Preclinical Models Unit, National Cancer Institute, INT Fondazione Pascale, Via Mariano Semmola, 80131 Naples, Italy
    Endocr Relat Cancer 13:3-6. 2006
    ..Taken together, these findings strongly support prospective clinical trials of anti-EGFR agents in cancer patients with bone metastases in order to define their role in the management of bone disease...
  8. doi request reprint Target-based therapies in breast cancer: current status and future perspectives
    Nicola Normanno
    Cell Biology and Biotherapy Unit, INT Fondazione Pascale, 80131 Naples, Italy
    Endocr Relat Cancer 16:675-702. 2009
    ..Therefore, a comprehensive approach that takes into account the complexity of the disease is definitely required to improve the efficacy of target-based therapy in breast cancer...
  9. ncbi request reprint Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling
    Nicola Normanno
    Cell Biology and Preclinical Models Unit, INT Fondazione Pascale, 80131, Naples, Italy
    Breast Cancer Res Treat 112:25-33. 2008
    ..These observations suggest that MAPK signaling might play a role in the resistance that develops in breast cancer cells after long-term exposure to gefitinib...
  10. ncbi request reprint CRIPTO-1: a novel target for therapeutic intervention in human carcinoma
    Nicola Normanno
    Department of Experimental Oncology, INT Fondazione Pascale, Via Mariano Semmola, I 80131 Naples, Italy
    Int J Oncol 25:1013-20. 2004
    ..Taken together, these data strongly suggest that CR-1 might represent a novel target for therapeutic intervention in different carcinoma types...
  11. doi request reprint Results of the First Italian External Quality Assurance Scheme for somatic EGFR mutation testing in non-small-cell lung cancer
    Nicola Normanno
    Research Department, Cell Biology and Biotherapy Unit, INT Fondazione G Pascale, Via M Semmola, Naples, Italy
    J Thorac Oncol 8:773-8. 2013
    ..The Italian Association of Medical Oncology (AIOM) and the Italian Society of Pathology and Cytology organized an external quality assessment (EQA) scheme for EGFR mutation testing in non-small-cell lung cancer...
  12. pmc KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment
    Nicola Normanno
    Cell Biology and Biotherapy Unit, INT Fondazione G Pascale, Naples, Italy
    PLoS ONE 6:e29146. 2011
    ..Therefore, KRAS testing has become mandatory to chose the most appropriate therapy for these patients...
  13. doi request reprint Molecular diagnostics and personalized medicine in oncology: challenges and opportunities
    Nicola Normanno
    Cell Biology and Biotherapy Unit, INT Fondazione Pascale, Naples, Italy
    J Cell Biochem 114:514-24. 2013
    ..By using these approaches, the development of personalized medicine for patients with cancer will finally become possible...
  14. ncbi request reprint Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development
    Nicola Normanno
    Cell Biology and Preclinical Models, INT Fondazione Pascale, 80131 Naples, Italy
    Front Biosci 10:2611-7. 2005
    ..In this regard, we describe potential future applications of these compounds in combination with other agents in the treatment of breast carcinoma...
  15. ncbi request reprint Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis
    N Normanno
    Cell Biology and Preclinical Models, INT Fondazione Pascale, Via Mariano Semmola, 80131 Naples, Italy
    Endocr Relat Cancer 12:471-82. 2005
    ..These data have demonstrated for the first time that the EGFR regulates the ability of BMSCs to induce osteoclast differentiation and strongly support clinical trials of gefitinib in breast cancer patients with bone disease...
  16. ncbi request reprint Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells
    Nicola Normanno
    Division of Haematological Oncology and Department of Experimental Oncology, INT Fondazione Pascale, Naples, Italy
    J Cell Physiol 198:31-9. 2004
    ..These findings suggest that CR-1 overexpression might be associated with the progression towards a more aggressive phenotype in breast carcinoma, through the activation of both Akt and Smad-2 signalling pathways...
  17. ncbi request reprint The ErbB receptors and their ligands in cancer: an overview
    N Normanno
    Cell Biology and Preclinical Models Unit, INT Fondazione Pascale, 80131 Naples, Italy
    Curr Drug Targets 6:243-57. 2005
    ..In this respect, the contemporary expression of different ErbB tyrosine kinases and/or EGF-like growth factors in human carcinomas might also affect tumor response to target based agents directed against the ErbB receptor/ligand system...
  18. ncbi request reprint Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth
    N Normanno
    Oncologia Sperimentale D, Istituto Tumori Milano, Milan, Italy
    Ann Oncol 13:65-72. 2002
    ..Co-expression of the epidermal growth factor receptor (EGFR) and of ErbB-2 is found in a subset of primary human breast cancer...
  19. ncbi request reprint Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment
    N Normanno
    Division of Hematological Oncology and Department of Experimental Oncology, INT Fondazione Pascale, 80131 Naples, Italy
    Endocr Relat Cancer 10:1-21. 2003
    ....
  20. ncbi request reprint Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
    Nicola Normanno
    Oncologia Sperimentale D, INT Fondazione Pascale, Naples, Italy
    J Cell Physiol 194:13-9. 2003
    ..On the basis that different signal transduction pathways contribute to the control of tumor growth, future therapeutic approaches are likely to involve combination of different targeted agents...
  21. ncbi request reprint Small molecule epidermal growth factor receptor tyrosine kinase inhibitors: an overview
    N Normanno
    Department of Experimental Oncology, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
    J Chemother 16:36-40. 2004
    ..This brief review summarizes the results of phase II monotherapy trials of EGFR TKIs in cancer patients. The molecular mechanisms involved in regulating the sensitivity/resistance of tumor cells to EGFR-TKIs are also discussed...
  22. ncbi request reprint The role of EGF-related peptides in tumor growth
    N Normanno
    Oncologia Sperimentale D, ITN Fondazione Pascale, 80131 Napoli, Italy
    Front Biosci 6:D685-707. 2001
    ..Taken together, these data strongly suggest that the EGF-like peptides are involved in the pathogenesis of human carcinomas, and that they might represent suitable targets for novel therapeutic approaches...
  23. pmc Right-sided rhabdoid colorectal tumors might be related to the serrated pathway
    Massimo Pancione
    Department of Biological, Geological and Environmental Sciences, University of Sannio, Benevento, Italy
    Diagn Pathol 8:31. 2013
    ..The differential diagnosis is with the malignant rhabdoid tumors of infancy characterized by genetic inactivation of SMARCB1 (INI1) or deletions of chromosome 22q12 locus...
  24. doi request reprint Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells
    Amelia D'Alessio
    Cell Biology and Biotherapy Unit, INT Fondazione Pascale, 80131, Naples, Italy
    Breast Cancer Res Treat 123:387-96. 2010
    ....
  25. ncbi request reprint The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib
    Nicola Normanno
    Cell Biology and Preclinical Models Unit, INT Fondazione Pascale, Naples, Italy
    J Cell Physiol 207:420-7. 2006
    ..Taken together, these data strongly support the role of the MEK/MAPK pathway in the resistance to gefitinib, and provide the rationale for novel therapeutic approaches based on combinations of signal transduction inhibitors...
  26. ncbi request reprint AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib
    Monica R Maiello
    Cell Biology and Preclinical Models Unit, National Cancer Institute INT Fondazione Pascale, Naples 80131, Italy
    Breast Cancer Res Treat 102:275-82. 2007
    ..These data suggest that AZD3409 might be active in gefitinib-resistant breast carcinoma...
  27. ncbi request reprint Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level
    Manuela Campiglio
    Molecular Targeting Unit, Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy
    J Cell Physiol 198:259-68. 2004
    ..Our data suggest that the antitumor activity of ZD1839 is due to a cytostatic effect, and involves apoptosis induction in a subset of sensitive cells only, and that neither MAPK nor Akt is a reliable marker of ZD1839 activity...
  28. doi request reprint Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach
    Pietro Carotenuto
    Pharmacogenomic Laboratory, Centro Ricerche Oncologiche di Mercogliano, Avellino, Italy
    Pharmacogenomics 11:1169-79. 2010
    ..Therefore, KRAS mutation testing of mCRC patients is mandatory in the clinical setting to aid in the choice of appropriate therapy...
  29. doi request reprint Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions
    Alessandro Morabito
    Clinical Trials Unit, National Cancer Institute, Napoli, Italy
    Oncologist 14:378-90. 2009
    ..Ongoing phase II and III clinical trials will better define the appropriate schedule, the optimal setting of evaluation, and the safety of long-term use of vandetanib...
  30. ncbi request reprint Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions
    Alessandro Morabito
    Clinical Trials Unit, National Cancer Institute, Via Mariano Semola, 80131 Naples, Italy
    Oncologist 11:753-64. 2006
    ....
  31. doi request reprint Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells
    Antonella De Luca
    Cell Biology and Biotherapy Unit, INT Fondazione Pascale, Naples, Italy
    J Cell Physiol 226:2131-8. 2011
    ..These data suggest that EGFR signaling regulates the ability of MSCs to sustain cancer progression through the release of growth factors that promote neo-angiogenesis and tumor cell migration...
  32. pmc Gefitinib in non small cell lung cancer
    Raffaele Costanzo
    Medical Oncology Unit, Thoraco Pulmonary Department, National Cancer Institute, 80131 Napoli, Italy
    J Biomed Biotechnol 2011:815269. 2011
    ..The results of these trials have demonstrated the efficacy of gefitinib that can be now considered as the standard first-line treatment of patients with advanced NSCLC harbouring activating EGFR mutations...
  33. ncbi request reprint Transforming growth factor alpha, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas
    Antonio D'Antonio
    Anatomia Patologica AORN Cardarelli, Naples, Italy
    Int J Oncol 21:941-8. 2002
    ..Finally, expression of TGFalpha was predictive of longer progression-free survival. These data strongly suggest that the EGF-related peptides might be involved in the pathogenesis and outcome of human ovarian cancer...
  34. doi request reprint Pharmacokinetic evaluation of capecitabine in breast cancer
    Gennaro Daniele
    Clinical Trials Unit, INT Fondazione Pascale, Naples, Italy
    Expert Opin Drug Metab Toxicol 9:225-35. 2013
    ..In metastatic breast cancer (MBC), capecitabine is an effective and well-tolerated therapeutic option both in monotherapy and in combination with chemotherapeutic or molecular-targeted agents...
  35. doi request reprint Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence
    Gennaro Daniele
    Clinical Trials Unit, National Cancer Institute, Via M Semmola 8013, Naples, Italy
    Expert Rev Anticancer Ther 11:299-307. 2011
    ..In conclusion, the entire matter remains one of the most intriguing in oncology, and data from ongoing and planned future studies will surely provide us with more information on the great potential of BPs in the adjuvant setting...
  36. doi request reprint Pharmacokinetic evaluation of zoledronic acid
    Antonella De Luca
    Cell Biology and Biotherapy Unit, INT Fondazione Pascale, 80131 Naples, Italy
    Expert Opin Drug Metab Toxicol 7:911-8. 2011
    ..Zoledronic acid (ZA) is the most potent of the clinically available bisphosphonates. In addition to its antiresorptive activity, there has been increasing evidence to suggest that it also has anticancer properties...
  37. doi request reprint New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development
    Massimo Di Maio
    National Cancer Institute, Clinical Trials Unit, Via Mariano Semmola, 80131 Naples, Italy
    Expert Opin Investig Drugs 19:1503-14. 2010
    ..Most of these drugs offer novel mechanisms of action compared with drugs currently used in clinical practice...
  38. ncbi request reprint Does the sequence of gemcitabine and vinorelbine affect their efficacy in non-small cell lung cancer in vitro?
    Antonella De Luca
    Department of Experimental Oncology, National Cancer Institute, Fondazione Pascale, Naples, Italy
    Anticancer Res 24:2985-9. 2004
    ....
  39. ncbi request reprint Triple negative breast cancer: from molecular portrait to therapeutic intervention
    Pietro Carotenuto
    Pharmacogenomic Laboratory, CROM Oncological Research Center Mercogliano, 83013 Avellino, Italy
    Crit Rev Eukaryot Gene Expr 20:17-34. 2010
    ....
  40. doi request reprint Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR
    Pietro Carotenuto
    Pharmacogenomic Laboratory, CROM Centro Ricerche Oncologiche di Mercogliano, Avellino, Italy
    Int J Oncol 40:378-84. 2012
    ....
  41. ncbi request reprint Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Massimo Di Maio
    Clinical Trials Unit, National Cancer Institute of Naples, Naples, Italy
    J Cell Physiol 205:355-63. 2005
    ....
  42. ncbi request reprint Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
    Nicola Normanno
    Cell Biology and Biotherapy Unit, INT Fondazione Pascale, Naples, Italy
    Nat Rev Clin Oncol 6:519-27. 2009
    ..We summarize the experimental and clinical evidence supporting the use of KRAS testing for the optimal selection of patients with mCRC to be treated with anti-EGFR monoclonal antibodies...
  43. pmc Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology
    Cristin Roma
    Laboratory of Pharmacogenomics, Centro di Ricerche Oncologiche di Mercogliano CROM, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale IRCCS, 83013 Mercogliano, Italy
    Biomed Res Int 2013:385087. 2013
    ..In conclusion, our data suggest that castPCR is highly sensitive and specific to detect EGFR mutations in NSCLC clinical samples. ..
  44. ncbi request reprint Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases
    Maria Pia Morelli
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Napoli, Italy
    J Cell Physiol 208:344-53. 2006
    ....
  45. doi request reprint A "live" biopsy in a small-cell lung cancer patient by detection of circulating tumor cells
    Simona Bevilacqua
    Cell Biology and Biotherapy Unit, INT Fondazione Pascale, Naples 80131, Italy
    Lung Cancer 65:123-5. 2009
    ..This study is the first to demonstrate that CTC can be identified in SCLC patients by using the CellSearch system...
  46. doi request reprint Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?
    Renato Franco
    Pathology Unit, National Cancer Institute, Pascale Hospital, Naples, Italy
    Expert Rev Anticancer Ther 13:407-20. 2013
    ..The authors summarize the strategies that in the future could overcome these mechanisms of escape...
  47. doi request reprint Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration
    Antonella De Luca
    Cell Biology and Biotherapy Unit, INT Fondazione Pascale, Naples, Italy
    J Cell Biochem 113:3363-70. 2012
    ..These results suggest that MSC-secreted IL-6 and VEGF may act as paracrine factors to sustain breast cancer cell migration...
  48. ncbi request reprint New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004
    Francesco Caponigro
    National Tumor Institute, Fondazione G Pascale, Naples, Italy
    Anticancer Drugs 16:211-21. 2005
    ..Phase I/II clinical trials have shown low toxicity and evidence of anti-tumor activity; on the other hand, this compound has potential for synergism with radiotherapy, chemotherapy and biologicals...
  49. ncbi request reprint The role of the EGFR signaling in tumor microenvironment
    Antonella De Luca
    Cell Biology and Preclinical Models Unit, INT Fondazione Pascale, Naples, Italy
    J Cell Physiol 214:559-67. 2008
    ..Taken together, these findings suggest that the EGFR system is an important mediator, within the tumor microenvironment, of autocrine and paracrine circuits that result in enhanced tumor growth...
  50. doi request reprint The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches
    Antonella De Luca
    Cell Biology and Biotherapy Unit, INT Fondazione Pascale, 80131 Naples, Italy
    Expert Opin Ther Targets 16:S17-27. 2012
    ..These signalling cascades are regulated by complex feedback and cross-talk mechanisms...
  51. ncbi request reprint Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors
    Antonella De Luca
    INT Fondazione Pascale, Cell Biology and Biotherapy Unit, Via Mariano Semmola, Naples, Italy
    IDrugs 13:636-45. 2010
    ..Clinical trials are currently ongoing to evaluate the safety and antitumor activity of tivozanib in breast, lung and colorectal cancer. Tivozanib might represent a promising anticancer agent in several different tumor types...
  52. doi request reprint Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?
    Antonio Rossi
    Division of Medical Oncology, S G Moscati Hospital, Avellino, Italy
    Cancer Treat Rev 39:489-97. 2013
    ..This review will summarize the current evidence that strongly support the hypothesis that gefitinib, erlotinib and afatinib are ideal drugs for NSCLC patients carrying EGFR mutations...
  53. doi request reprint Leptin signaling in breast cancer: an overview
    Donatella Cirillo
    Protein Chemistry Laboratory, Centro di Ricerche Oncologiche di Mercogliano CROM, Mercogliano AV, Italy
    J Cell Biochem 105:956-64. 2008
    ..Taken together, these findings suggest that the leptin system might play an important role in breast cancer pathogenesis and progression, and that it might represent a novel target for therapeutic intervention in breast cancer...
  54. doi request reprint Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia
    Fortunato Ciardiello
    Division of Medical Oncology, Department of Experimental and Clinical Medicine and Surgery F Magrassi and A Lanzara, Second University of Naples, Via S Pansini 5, 80131, Naples, Italy
    Target Oncol 6:133-45. 2011
    ..In conclusion, KRAS testing is now widely established as a routine diagnostic procedure for patients with mCRC and is used increasingly to guide treatment selection...
  55. ncbi request reprint Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors
    Francesco Caponigro
    Division of Medical Oncology B, National Tumor Institute of Naples, Fondazione G Pascale, Naples, Italy
    Curr Opin Oncol 17:212-7. 2005
    ..To discuss future therapeutic strategies...
  56. pmc Epithelial to mesenchymal transition by TGFβ-1 induction increases stemness characteristics in primary non small cell lung cancer cell line
    Giuseppe Pirozzi
    Department of Experimental Oncology, National Cancer Institute, Naples, Italy
    PLoS ONE 6:e21548. 2011
    ..The aim of this study is to shed light on the relationship between EMT and CSCs by using LC31 lung cancer primary cell line...